COPENHAGEN, Denmark, June 2 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) today announced that David A. Eatwell has been appointed Chief Financial Officer of the company. Mr. Eatwell will be responsible for overseeing the financial and accounting activities of the company.
David A. Eatwell, 47, joins Genmab with extensive experience and a proven track record in leading international life science businesses, having spent 15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD 1.8 billion leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry, with 33 facilities in 12 countries and 10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of healthcare products and services, where he spearheaded the USD 3.3 billion sale of the Pharmaceutical Technologies and Services division to The Blackstone Group and was instrumental in creating the framework and building the infrastructure to support the newly created company, Catalent Pharma Solutions, Inc. Mr. Eatwell is a Chartered Accountant.
Mr. Eatwell is replacing Bo Kruse who has decided to seek new challenges elsewhere, but will during a transitional period be available for the company.
“We are very excited to have David Eatwell on board to be part of our Senior Management team and we are looking forward to working with him. We also wish to thank Bo Kruse for his many years of dedicated service to Genmab, and important contributions to the company. We wish Bo Kruse the best of luck in his future endeavors and would like to thank him for his efforts at Genmab since 2000", said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
About Genmab A/S Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab’s world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit http://www.genmab.com.
This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45-33-44-77 30, M: +45-25-27-47-13, E: hth@genmab.com
Stock Exchange Release no. 27/2008
CONTACT: Contact: Helle Husted, Sr. Director, Investor Relations, T:
+45-33-44-77 30, M: +45-25-27-47-13, E: hth@genmab.com
